StockNews.com Begins Coverage on Arcadia Biosciences (NASDAQ:RKDA)

Equities research analysts at StockNews.com began coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research report issued to clients and investors on Thursday. The brokerage set a “sell” rating on the basic materials company’s stock.

Arcadia Biosciences Trading Up 1.3 %

Shares of NASDAQ RKDA opened at $3.91 on Thursday. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $10.31. The company has a market capitalization of $5.34 million, a price-to-earnings ratio of -0.91 and a beta of 0.88. The business has a 50 day simple moving average of $5.05 and a 200-day simple moving average of $4.04.

Institutional Investors Weigh In On Arcadia Biosciences

An institutional investor recently bought a new position in Arcadia Biosciences stock. Geode Capital Management LLC acquired a new stake in shares of Arcadia Biosciences, Inc. (NASDAQ:RKDA) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned 0.90% of Arcadia Biosciences at the end of the most recent reporting period. 17.73% of the stock is currently owned by institutional investors and hedge funds.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.